South Korea · Delayed Price · Currency is KRW KBIO LABS Statistics
Total Valuation
KBIO LABS has a market cap or net worth of KRW 26.91 billion. The enterprise value is 11.09 billion.
| Market Cap | 26.91B |
| Enterprise Value | 11.09B |
Important Dates
The last earnings date was Wednesday, May 27, 2026.
| Earnings Date | May 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KBIO LABS has 23.10 million shares outstanding. The number of shares has increased by 0.34% in one year.
| Current Share Class | 23.10M |
| Shares Outstanding | 23.10M |
| Shares Change (YoY) | +0.34% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 15.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.31 |
| PB Ratio | 0.26 |
| P/TBV Ratio | 0.52 |
| P/FCF Ratio | 3.30 |
| P/OCF Ratio | 3.28 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.55, with an EV/FCF ratio of 1.36.
| EV / Earnings | -3.46 |
| EV / Sales | 0.13 |
| EV / EBITDA | 6.55 |
| EV / EBIT | 14.67 |
| EV / FCF | 1.36 |
Financial Position
The company has a current ratio of 5.20, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.20 |
| Quick Ratio | 4.62 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.35 |
| Debt / FCF | 0.07 |
| Interest Coverage | 14.01 |
Financial Efficiency
Return on equity (ROE) is -4.82% and return on invested capital (ROIC) is 1.72%.
| Return on Equity (ROE) | -4.82% |
| Return on Assets (ROA) | 0.40% |
| Return on Invested Capital (ROIC) | 1.72% |
| Return on Capital Employed (ROCE) | 0.74% |
| Weighted Average Cost of Capital (WACC) | 9.26% |
| Revenue Per Employee | 2.24B |
| Profits Per Employee | -82.04M |
| Employee Count | 39 |
| Asset Turnover | 0.74 |
| Inventory Turnover | 13.65 |
Taxes
In the past 12 months, KBIO LABS has paid 162.07 million in taxes.
| Income Tax | 162.07M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.98% in the last 52 weeks. The beta is 0.92, so KBIO LABS's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | -16.98% |
| 50-Day Moving Average | 1,662.32 |
| 200-Day Moving Average | 1,407.28 |
| Relative Strength Index (RSI) | 33.79 |
| Average Volume (20 Days) | 861,554 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KBIO LABS had revenue of KRW 87.31 billion and -3.20 billion in losses. Loss per share was -138.51.
| Revenue | 87.31B |
| Gross Profit | 12.52B |
| Operating Income | 755.63M |
| Pretax Income | -4.88B |
| Net Income | -3.20B |
| EBITDA | 1.69B |
| EBIT | 755.63M |
| Loss Per Share | -138.51 |
Balance Sheet
The company has 65.43 billion in cash and 585.81 million in debt, with a net cash position of 64.85 billion or 2,807.36 per share.
| Cash & Cash Equivalents | 65.43B |
| Total Debt | 585.81M |
| Net Cash | 64.85B |
| Net Cash Per Share | 2,807.36 |
| Equity (Book Value) | 102.28B |
| Book Value Per Share | 2,305.61 |
| Working Capital | 68.13B |
Cash Flow
In the last 12 months, operating cash flow was 8.20 billion and capital expenditures -35.84 million, giving a free cash flow of 8.16 billion.
| Operating Cash Flow | 8.20B |
| Capital Expenditures | -35.84M |
| Depreciation & Amortization | 937.55M |
| Net Borrowing | -772.90M |
| Free Cash Flow | 8.16B |
| FCF Per Share | 353.27 |
Margins
Gross margin is 14.34%, with operating and profit margins of 0.87% and -3.66%.
| Gross Margin | 14.34% |
| Operating Margin | 0.87% |
| Pretax Margin | -5.59% |
| Profit Margin | -3.66% |
| EBITDA Margin | 1.94% |
| EBIT Margin | 0.87% |
| FCF Margin | 9.35% |
Dividends & Yields
KBIO LABS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.34% |
| Shareholder Yield | -0.34% |
| Earnings Yield | -11.89% |
| FCF Yield | 30.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 14, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Apr 14, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
KBIO LABS has an Altman Z-Score of 1.91 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.91 |
| Piotroski F-Score | 4 |